Bacille Calmette Guérin vaccination in pre-term infants

Area of Science:

• Immunology
• Neonatal Medicine
• Vaccinology

Background:

• The Bacillus Calmette Guerin (BCG) vaccine is crucial for preventing tuberculosis.
• Understanding BCG vaccine efficacy in preterm neonates is essential for optimizing immunization strategies.

Purpose of the Study:

• To assess the effectiveness of the BCG vaccine in preterm infants.
• To compare BCG vaccine response in preterm infants vaccinated at birth versus post-conceptional age.

Main Methods:

• Three groups of neonates received BCG vaccine: preterm infants at birth (n=36), preterm infants at 40 weeks post-conceptional age (n=16), and full-term infants at birth (n=20).
• Purified protein derivative (PPD) testing was conducted 2-4 months post-vaccination to evaluate immune response.

Main Results:

• Full-term infants showed the largest BCG scars and PPD induration, while preterm infants vaccinated at birth had the smallest.
• Lower gestational age (27-33 weeks) in preterm infants correlated with smaller BCG scars and PPD induration compared to those with higher gestational age (34-36 weeks).
• Female infants were more likely to develop BCG scars, and both birth weight and female sex were associated with a reactive PPD test.

Conclusions:

• Male preterm infants with gestational age below 33 weeks exhibit a reduced likelihood of developing BCG scars and reactive PPD tests.
• Routine BCG vaccination at birth is not recommended for preterm neonates with a gestational age below 33 weeks.
• Further research with larger cohorts is necessary to validate these findings regarding BCG vaccine efficacy in preterm infants.